Markers of cognitive decline in PD: The case for heterogeneity.
Identifieur interne : 000293 ( Main/Exploration ); précédent : 000292; suivant : 000294Markers of cognitive decline in PD: The case for heterogeneity.
Auteurs : Oury Monchi [Canada] ; Alexandru Hanganu [Canada] ; Pierre Bellec [Canada]Source :
- Parkinsonism & related disorders [ 1873-5126 ] ; 2016.
English descriptors
- KwdEn :
- MESH :
- chemical , metabolism : Biomarkers.
- complications : Parkinson Disease.
- diagnostic imaging : Parkinson Disease.
- etiology : Cognition Disorders.
- Genetic Heterogeneity, Humans, Neuroimaging, Neuropsychological Tests.
Abstract
Cognitive impairment is highly prevalent and has a severe negative effect on health related and perceived quality of life in Parkinson's disease (PD). It is now established that 20-40% of persons with PD will develop cognitive deficits early in the disease. Moreover, the risk of developing dementia is six times higher in PD patients than in age-matched controls and it is estimated that 80% of patients will develop dementia after 20 years of the disease. In order to address these symptoms properly it is crucial to identify very early in the disease the patients who are most likely to develop dementia rapidly. Persons who meet criteria for mild cognitive impairment (MCI) exhibit measurable cognitive deficits but those deficits are not severe enough to interfere significantly with daily life. While the presence of MCI in PD increases the chance of developing dementia, various studies suggest that PD-MCI might consist of distinct subtypes with different pathophysiologies and prognoses. In this paper we comment on various biomarkers associated with cognitive decline in PD, specifically clinical, neuropathological, genetic and neuroimaging ones. We also discuss disrupted functional connectivity in PD-MCI and reveal preliminary results from our own group. We propose that the current studies looking at different types of biomarkers provide support for different causes being associated with cognitive decline in PD. Large-scale multi-disciplinary and multi-modal longitudinal studies are required to identify more specifically the different phenotypes associated with different cognitive profiles and evolution in PD.
DOI: 10.1016/j.parkreldis.2016.01.002
PubMed: 26774536
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000287
- to stream PubMed, to step Curation: 000287
- to stream PubMed, to step Checkpoint: 000287
- to stream Ncbi, to step Merge: 001E42
- to stream Ncbi, to step Curation: 001E42
- to stream Ncbi, to step Checkpoint: 001E42
- to stream Main, to step Merge: 000294
- to stream Main, to step Curation: 000293
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Markers of cognitive decline in PD: The case for heterogeneity.</title><author><name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name><affiliation wicri:level="4"><nlm:affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada; Centre de recherche, Institut universitaire de Gériatrie de Montréal, Université de Montréal, Montréal, QC, Canada. Electronic address: oury.monchi@ucalgary.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada; Centre de recherche, Institut universitaire de Gériatrie de Montréal, Université de Montréal, Montréal, QC</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Hanganu, Alexandru" sort="Hanganu, Alexandru" uniqKey="Hanganu A" first="Alexandru" last="Hanganu">Alexandru Hanganu</name><affiliation wicri:level="4"><nlm:affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Bellec, Pierre" sort="Bellec, Pierre" uniqKey="Bellec P" first="Pierre" last="Bellec">Pierre Bellec</name><affiliation wicri:level="1"><nlm:affiliation>Centre de recherche, Institut universitaire de Gériatrie de Montréal, Université de Montréal, Montréal, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de recherche, Institut universitaire de Gériatrie de Montréal, Université de Montréal, Montréal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26774536</idno><idno type="pmid">26774536</idno><idno type="doi">10.1016/j.parkreldis.2016.01.002</idno><idno type="wicri:Area/PubMed/Corpus">000287</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000287</idno><idno type="wicri:Area/PubMed/Curation">000287</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000287</idno><idno type="wicri:Area/PubMed/Checkpoint">000287</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000287</idno><idno type="wicri:Area/Ncbi/Merge">001E42</idno><idno type="wicri:Area/Ncbi/Curation">001E42</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E42</idno><idno type="wicri:Area/Main/Merge">000294</idno><idno type="wicri:Area/Main/Curation">000293</idno><idno type="wicri:Area/Main/Exploration">000293</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Markers of cognitive decline in PD: The case for heterogeneity.</title><author><name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name><affiliation wicri:level="4"><nlm:affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada; Centre de recherche, Institut universitaire de Gériatrie de Montréal, Université de Montréal, Montréal, QC, Canada. Electronic address: oury.monchi@ucalgary.ca.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada; Centre de recherche, Institut universitaire de Gériatrie de Montréal, Université de Montréal, Montréal, QC</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Hanganu, Alexandru" sort="Hanganu, Alexandru" uniqKey="Hanganu A" first="Alexandru" last="Hanganu">Alexandru Hanganu</name><affiliation wicri:level="4"><nlm:affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; Department of Radiology, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author><author><name sortKey="Bellec, Pierre" sort="Bellec, Pierre" uniqKey="Bellec P" first="Pierre" last="Bellec">Pierre Bellec</name><affiliation wicri:level="1"><nlm:affiliation>Centre de recherche, Institut universitaire de Gériatrie de Montréal, Université de Montréal, Montréal, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Centre de recherche, Institut universitaire de Gériatrie de Montréal, Université de Montréal, Montréal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author></analytic><series><title level="j">Parkinsonism & related disorders</title><idno type="eISSN">1873-5126</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biomarkers (metabolism)</term><term>Cognition Disorders (etiology)</term><term>Genetic Heterogeneity</term><term>Humans</term><term>Neuroimaging</term><term>Neuropsychological Tests</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (diagnostic imaging)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Genetic Heterogeneity</term><term>Humans</term><term>Neuroimaging</term><term>Neuropsychological Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive impairment is highly prevalent and has a severe negative effect on health related and perceived quality of life in Parkinson's disease (PD). It is now established that 20-40% of persons with PD will develop cognitive deficits early in the disease. Moreover, the risk of developing dementia is six times higher in PD patients than in age-matched controls and it is estimated that 80% of patients will develop dementia after 20 years of the disease. In order to address these symptoms properly it is crucial to identify very early in the disease the patients who are most likely to develop dementia rapidly. Persons who meet criteria for mild cognitive impairment (MCI) exhibit measurable cognitive deficits but those deficits are not severe enough to interfere significantly with daily life. While the presence of MCI in PD increases the chance of developing dementia, various studies suggest that PD-MCI might consist of distinct subtypes with different pathophysiologies and prognoses. In this paper we comment on various biomarkers associated with cognitive decline in PD, specifically clinical, neuropathological, genetic and neuroimaging ones. We also discuss disrupted functional connectivity in PD-MCI and reveal preliminary results from our own group. We propose that the current studies looking at different types of biomarkers provide support for different causes being associated with cognitive decline in PD. Large-scale multi-disciplinary and multi-modal longitudinal studies are required to identify more specifically the different phenotypes associated with different cognitive profiles and evolution in PD.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Alberta</li></region><settlement><li>Calgary</li></settlement><orgName><li>Université de Calgary</li></orgName></list><tree><country name="Canada"><region name="Alberta"><name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name></region><name sortKey="Bellec, Pierre" sort="Bellec, Pierre" uniqKey="Bellec P" first="Pierre" last="Bellec">Pierre Bellec</name><name sortKey="Hanganu, Alexandru" sort="Hanganu, Alexandru" uniqKey="Hanganu A" first="Alexandru" last="Hanganu">Alexandru Hanganu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000293 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000293 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26774536
|texte= Markers of cognitive decline in PD: The case for heterogeneity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26774536" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |